Research Article

Noninterventional Study of Transdermal Fentanyl (Fentavera) Matrix Patches in Chronic Pain Patients: Analgesic and Quality of Life Effects

Table 6

Summary of total adverse events during 2 months treatment with the transdermal fentanyl (Fentavera) patch.


Preferred terms (MedDRA)
 Nausea6
 Vomiting3
 Vertigo 2
 Restlessness 2
 Abdominal pain upper 2
 Fatigue 1
 Sedation 1
 Dysphoria1
 Retching1
 Feeling abnormal1
 Dyspnoea1
 Confusional state1
 Rash1
 Death1
 Dermatitis allergic1
 Pain1
 Diarrhoea1
 Swelling1
 Headache1
 Depressive symptom1
System-Organ-Class (SOC) (MedDRA)
 Gastrointestinal disorders13
 General disorders and administration site conditions5
 Psychiatric disorders5
 Ear and labyrinth disorders2
 Nervous system disorders2
 Skin and subcutaneous tissue disorders2
 Respiratory, thoracic, and mediastinal disorders1
Outcome
 Recovered 16
 Unknown1
 Fatal 1
 Life-threatening3
Causality assessment
 Certain 4
 Probable9
 Possible 2
 Unlikely3